KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Operating Expenses (2018 - 2025)

Alnylam Pharmaceuticals' Other Operating Expenses history spans 10 years, with the latest figure at $267.7 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 160.39% year-over-year to $267.7 million; the TTM value through Dec 2025 reached $681.9 million, up 110.86%, while the annual FY2025 figure was $681.9 million, 110.86% up from the prior year.
  • Other Operating Expenses reached $267.7 million in Q4 2025 per ALNY's latest filing, up from $200.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $267.7 million in Q4 2025 to a low of $31.1 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $81.2 million, with a median of $67.3 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: decreased 19.56% in 2024, then soared 160.39% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $37.7 million in 2021, then skyrocketed by 36.11% to $51.3 million in 2022, then soared by 67.48% to $85.9 million in 2023, then grew by 19.75% to $102.8 million in 2024, then skyrocketed by 160.39% to $267.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Other Operating Expenses are $267.7 million (Q4 2025), $200.2 million (Q3 2025), and $143.0 million (Q2 2025).